- Zacks•11 hours ago
Given the current scenario of increased political, media and public pressure on drug pricing, it makes sense to zero in on companies that are in the biosimilars business.
- PR Newswire•13 hours agoDebiopharm International SA Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer in Cancer Immunotherapy
LAUSANNE, Switzerland, October 20, 2016 /PRNewswire/ -- This joint effort will initially focus on a Phase I/Ib trial in patients with Lung Cancer to assess safety and preliminary efficacy of Debio 1143 ...
Pfizer Inc. (PFE)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||32.52 x 1900|
|Ask||32.56 x 200|
|Day's Range||32.49 - 32.74|
|52wk Range||28.25 - 37.39|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||28.85|
|Avg Vol (3m)||18,678,366|
|Dividend & Yield||1.20 (3.67%)|